Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia

Annals of Pharmacotherapy

Volumn 48, Issue 10, 2014, Pages 1356-1361

  Shah, Arpita ^a  

^a AUGUSTA UNIVERSITY   (United States)

Author keywords

chlorambucil; GA101; obinutuzumab; untreated chronic lymphocytic leukemia

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; CHLORAMBUCIL; MONOCLONAL ANTIBODY; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INFECTION; INFUSION RELATED REACTION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VOLUME OF DISTRIBUTION; DISEASE FREE SURVIVAL; FOOD AND DRUG ADMINISTRATION; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907369690     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014543271     Document Type: Review

References (39)

1. Siegel R,Ma J,Zou Z, et al.Cancer statistics, 2014.CA Cancer J Clin. 2014;64:9-29.
2. Hallek M.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Am J Hematol. 2013;88:803-816.
3. National Comprehensive Cancer Network. Non-Hodgkin's lymphoma: version 2.2014. NCCN Clinical Practice Guidelines in Oncology. www.nccn.org. Accessed March 31, 2014.
4. Jaglowski SM,Alinari L,Lapalombella R, et al.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Blood. 2010;116:3705-3714.
5. Cuneo A,Cavazzini F,Ciccone M, et al.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.Cancer Med. 2014;3:555-564.
6. Rossi D,Rasi S,Spina V, et al.Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.Blood. 2013;121:1403-1412.
7. Foa R,Guarini A.A mechanism-driven treatment for chronic lymphocytic leukemia?.N Engl J Med. 2013;369:85-87.
8. Hallek M.Signaling the end of chronic lymphocytic leukemia: new frontline strategies.Blood. 2013;122:3723-3734.
9. Terasawa T,Trikalinos NA,Djulbegovic B, et al.Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis.Cancer Treat Rev. 2013;39:340-349.
10. Cheson BD.Monoclonal antibody therapy of chronic lymphocytic leukemia.Best Pract Res Clin Haematol. 2010;23:133-143.
11. Hallek M,Fingerle-Rowson G,Fink A-M, et al.First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia: results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group [abstract 535].Blood. 2009;114 (22):.
12. Eichhorst B,Dreyling M,Robak T, et al.Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up.Ann Oncol. 2011;:vi50-vi54.
13. Goede V,andHallek M.Optimal pharmacotherapeutic management of chronic lymphocytic leukemia.Drugs Aging. 2011;28:163-176.
14. Rituximab (Rituxan) [product information].San Francisco, CA: Roche Pharmaceutical Inc; 1997. http://www.gene.com/download/pdf/rituxan_prescribing.pdf. Accessed March 1, 2014.
15. Fischer KJ,Bahlo AM,Fink R, et al.Chemoimmunotherapy based treatment for CLL: extended follow up of the CLL8 protocol, a randomized phase III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with CLL: results on survival, progression free survival, delayed neutropenia and secondary malignancies confirm superiority of FCR regimen [abstract 435].Blood. 2012;:120.
16. Ofatumumab (Arzerra) [product information].Brentford, UK: Glaxo Group Limited; 2009. www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf. Accessed March 1, 2014.
17. Obinutuzumab (Gazyva) [product information].San Francisco, CA: Genentech Inc; 2013. http://www.gene.com/download/pdf/gazyva_prescribing.pdf. Accessed March 1, 2014.
18. Lee HZ,Miller BW,Kwitkowski VE, et al.U.S. Food and Drug Administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.Clin Cancer Res.
19. Dyer M.Safety and efficacy of atumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia.Ther Adv Hematol. 2012;3:199-207.
20. Jaglowski S,andByrd JC.Rituximab in chronic lymphocytic leukemia.Semin Hematol. 2010;47:156-169.
21. Golay J,Roit FD,Bologna L, et al.Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.Blood. 2013;122:3482-3491.
22. Rafiq S,Butchar JP,Cheney C, et al.Comparative assessment of clinically utilized CD-20 directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.J Immunol. 2013;190:2702-2711.
23. Mancheril BG,Waddell A,Dolimando DA, et al.Drug monographs: afatinib and obinutuzumab.Hosp Pharm. 2014;49:237-241.
24. Cameron F,McCormack PL.Obinutuzumab: first global approval.Drugs. 2014;74:147-154.
25. Klein C,Lammens A,Schäfer W, et al.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.MAbs. 2013;5:22-33.
26. Sehn LH,Assouline SE,Stewart DA, et al.A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.Blood. 2012;119:5118-5125.
27. Brown JR,O'Brien S,Kingsley CD, et al.Safety and efficacy of obinutuzumab with fludarabine/cyclophosphamide or bendamustine in the initial therapy of patients with chronic lymphocytic leukemia: results from phase 1b Galton trial (GA04779g) [abstract 523].Blood. 2013;122 (21):.
28. Morschhauser F,Cartron G,Lamy T, et al.Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract 884].Blood. 2009;114 (22):.
29. Cartron G,Morschhauser F,Thieblemont C, et al.Results from a phase II study of obinutuzumsalab monotherapy in relapsed/refractory CLL [abstract 0101].Haematologica. 2011;96:39-40.
30. Morschhauser F,Salles G,Cartron G, et al.Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101): a rational approach [abstract].Haematologica. 2011;96:935.
31. Goede V,Fischer K,Busch R, et al.Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.N Engl J Med. 2014;370:1101-1110.
32. Bottcher S,Ritgen M,Fishcer K, et al.Minimal residual disease quantification is an independent predictor or progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.J Clin Oncol. 2012;30:980-988.
33. Redbook [online database]. http://www.redbook.com/redbook/online. Accessed June 20, 2014.
34. Eichhorst B,Fink AM,Busch R, et al.Chemoimmunotherapy with fludarabine, cyclosphosphamide, and rituximab versus bendamustine and rituximab in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia: results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Group [abstract 526]. Abstract presented at: 54th American Society of Hematology Annual Meeting and Exposition; New Orleans, LA
35. Kharfan-Dabaja MA,Wierda WG,Cooper LJN.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Leukemia. 2014;28:507-517.
36. Hillmen P,Skotnicki AB,Robak T, et al.Alemtuzuamb compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.J Clin Oncol. 2007;25:5616-5623.
37. Stilgenbauer S and,Dohner H.Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.N Engl J Med. 2002;347:452-453.
38. Lozanski G,Heerema NA,Flinn IW, et al.Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Blood. 2004;103:3278-3281.
39. Jones JA,Byrd J.How will B-cell-receptor-targeted therapies change future of CLL therapy?.Blood. 2014;123:1455-1460.